Lipocine Reports Third-Quarter Revenue of $2.29 Million, EPS Loss of $0.08
Lipocine said revenue increased year over year and its net loss narrowed. Revenue included a $1.5 million collaboration fee, $600,000 in licensing revenue and TLANDO royalties; lower research and development expenses also helped narrow the loss.
Story updates
02:43:31 PM UTC
SquawkNews
Lipocine reported third-quarter 2026 revenue of $2.3 million, up from $115,000 a year earlier, and a net loss of $0.7 million. The company ended September with $21.5 million in unrestricted cash, cash equivalents and marketable securities. Its update included progress on its postpartum depression p…
Lipocine’s revenue increased year over year, while its net loss narrowed. Revenue benefited from a $1.5 million collaboration fee, $600,000 in licensing revenue and TLANDO royalties; lower research and development expenses also helped narrow the loss.Financial Highlights¹ Reported as “Total revenue…